AWA
LRMR icon

Artemis Wealth Advisors’s Larimar Therapeutics LRMR Stock Holding History

Artemis Wealth Advisors’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-745
Closed -$9.92K – 106
2019
Q4 		$9.92K Buy
+745
New +$7.12K ﹤0.01% 105

Other funds holding LRMR

AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
Soleus Capital Management
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Artemis Wealth Advisors's LRMR Position: Q1 2020 in Review

Artemis Wealth Advisors sold out of Larimar Therapeutics (LRMR) in Q1 2020, closing a stake of 745 shares — an estimated $9.92K sold.

Artemis Wealth Advisors first reported a position in LRMR in Q4 2019 and held it in 1 quarter. The position peaked at $9.92K in Q4 2019. 42 funds tracked by Wall St. Rank hold LRMR as of Q1 2020.

  • Artemis Wealth Advisors reported no remaining Larimar Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Artemis Wealth Advisors sold 745 Larimar Therapeutics shares in Q1 2020, an estimated $9.92K.
  • Artemis Wealth Advisors first reported a position in Larimar Therapeutics in Q4 2019 and held it in 1 quarter.
  • Artemis Wealth Advisors's Larimar Therapeutics position peaked at $9.92K in Q4 2019.
  • 42 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2020.

Based on Artemis Wealth Advisors's 13F filing for Q1 2020, filed 17 Feb 2023.